Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Exogenus Therapeutics selected to present at the European Innovation Council’s Investor Day on Health
Exogenus was the only Portuguese company selected to pitch at the European Innovation Council’s Investor Day on Health on May 18th and 19th to present its pioneering technology to leading...
Labiotech.eu just published an article featuring the interview with Exogenus’ CEO and CSO, Joana Correia, discussing the disparity in funding opportunities seen in Europe vs USA. The...